

Noroclav 250 mg Tablets for dogs

Authorised

- Potassium clavulanate
- Amoxicillin trihydrate

Product identification

Medicine name:

Noroclav 250 mg Tablets for dogs

Active substance:

Potassium clavulanate

Amoxicillin trihydrate

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Potassium clavulanate

59.56 milligram(s) / 1.00 Tablet

Amoxicillin trihydrate

229.61 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CR02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

The product is supplied in high-density polyethylene tubs with a polyethylene screw cap lid containing 100 tablets.

The product is supplied in high-density polyethylene tubs with a polyethylene screw cap lid containing 250 tablets.

The product is presented in packs of 2 blister strips (aluminium-aluminium) each containing 5 tablets per strip.

The product is presented in packs of 4 blister strips (aluminium-aluminium) each containing 5 tablets per strip.

The product is presented in packs of 10 blister strips (aluminium-aluminium) each containing 5 tablets per strip.

The product is presented in packs of 20 strips (aluminium-aluminium) each containing 5 tablets per strip.

The product is also presented in packs of 50 blister strips (aluminium-aluminium) each containing 5 tablets per strip.

Additional information

Entitlement type:

Marketing Authorisation

Marketing authorisation holder:

Norbrook Laboratories (Ireland) Limited

Marketing authorisation date:

11/06/2004

Manufacturing sites for batch release:

Norbrook Laboratories Limited

Norbrook Manufacturing Limited

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 10197

Date of authorisation status change:

27/01/2022

Reference member state:

Ireland

Procedure number:

IE/V/0546/002

Concerned member states:

Austria Belgium Denmark France Luxembourg Netherlands Norway Portugal
Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to

www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 13/04/2025

[Download](#)

Summary of Product Characteristics